STOCKS TELEGRAPH

Tag: Clearmind Medicine

  • 3 Stocks Building Momentum Fast: Clearmind Medicine (CMND), China Pharma (CPHI), Cardiol Therapeutics (CRDL)

    3 Stocks Building Momentum Fast: Clearmind Medicine (CMND), China Pharma (CPHI), Cardiol Therapeutics (CRDL)

    The search for high-growth opportunities has led many investors to explore under-the-radar stocks that may be on the verge of significant breakthroughs. Particularly within the healthcare space, companies advancing novel therapies or addressing unmet medical needs are starting to stand out as compelling prospects.

    Clearmind Medicine Inc (CMND)

    Clearmind Medicine Inc (NASDAQ: CMND) opened the trading on April 13, 2026, with great promise as it jumped 11.72% to $1.43. During the day, the stock rose to $1.49 and sunk to $1.26. Taking a more long-term approach, CMND posted a 52-week range of $0.59-$52.40.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 39.75%. Meanwhile, its Annual Earning per share during the time was 39.75%.  This publicly-traded company’s shares outstanding now amounts to $2.09 million. The organization now has a market capitalization sitting at $2.98 million.

    China Pharma Holdings Inc (CPHI)

    China Pharma Holdings Inc (AMEX: CPHI) started the day on April 13, 2026, with a price increase of 0.60% at $0.65. During the day, the stock rose to $0.65 and sunk to $0.65. Taking a more long-term approach, CPHI posted a 52-week range of $0.50-$2.60.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 53.14% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 53.14%.  This publicly-traded company’s shares outstanding now amounts to $40.52 million, simultaneously with a float of $18.89 million. The organization now has a market capitalization sitting at $26.33 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term growth profile through pipeline diversification, extending beyond its lead oral therapy into next-generation treatments targeting large-scale cardiovascular markets. This strategic expansion reflects a broader ambition to address both rare inflammatory conditions and widespread chronic diseases.

    Market Momentum

    As of April 13, 2026, CRDL closed at $1.3600, down 1.45%, with trading volume (243,619 shares) well below its average of 589,930 shares—indicating reduced near-term activity and consolidation. With a market cap of $151.885M, the stock remains within its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.48 continues to suggest significant upside potential, supported by upcoming development milestones.

    Pipeline Expansion: CRD-38

    The company is advancing CRD-38, a subcutaneous therapy designed for heart failure with preserved ejection fraction (HFpEF), a condition affecting approximately half of all heart failure patients globally. Despite its prevalence, there are currently no approved therapies specifically targeting inflammation in HFpEF, creating a substantial unmet need.

    Preclinical Rationale

    Preclinical studies indicate that CRD-38 may reduce fibrosis, prevent cardiac hypertrophy, and protect against functional decline—key drivers of heart failure progression. By addressing both inflammation and structural damage, the therapy has the potential to offer a more comprehensive treatment approach.

    Outlook

    As CRD-38 moves toward clinical development, it represents a significant opportunity to expand Cardiol’s addressable market. Success in this program could position the company as a broader cardiovascular innovator beyond its initial niche focus.

  • Regulatory Approval Sends Clearmind Medicine (CMND) Soaring Pre-Market

    Regulatory Approval Sends Clearmind Medicine (CMND) Soaring Pre-Market

    As of the most recent premarket check, shares of Clearmind Medicine Inc. (NASDAQ: CMND) are up 69.67% to $2.07, a fantastic increase. This spike comes after it was announced that its Phase I/IIa clinical study of CMND-100, an experimental medication that targets alcohol use disorder or AUD, has received Institutional Review Board (IRB) clearance.

    Clinical Trial to Be Led by Yale School of Medicine

    Dr. Anahita Bassir Nia, MD, a renowned specialist in psychiatry and addiction medicine, will preside over the study, which is scheduled to begin at Yale School of Medicine’s Department of Psychiatry. With this crucial milestone, Clearmind Medicine’s FDA-regulated clinical program has advanced significantly, allowing for more assessment of the safety, tolerability, and effectiveness of CMND-100.

    Handling an International Health Emergency 

    High costs, minimal effectiveness of less than 30%, and poor patient compliance because to negative side effects are the main obstacles to the current AUD therapy choices. By launching CMND-100, which is ideally positioned to solve these issues and offer AUD sufferers a game-changing treatment, Clearmind Medicine seeks to close this gap. 

    Focus on Reducing Alcohol Cravings

    The upcoming trial will evaluate CMND-100’s potential to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. Data from this study will be instrumental in advancing the investigational drug through Clearmind’s clinical development pipeline.

    Collaborative Innovation with Dr. Glitter Pty Ltd

    In a related development, Clearmind Medicine recently signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology firm specializing in ActivCrystal technology. This groundbreaking oral delivery format encapsulates active ingredients in tasteless, odorless crystals that can be sprinkled on food.

    The partnership aims to integrate CMND’s MEAI-based alcohol substitute with ActivCrystal technology, paving the way for innovative solutions in treating AUD. A definitive agreement outlining the collaboration’s framework is expected to follow. These strategic advancements highlight Clearmind Medicine’s commitment to addressing critical gaps in AUD treatment through innovation and collaboration.

  • How Clearmind (CMND) Stock Is Securing A Stronger Position

    How Clearmind (CMND) Stock Is Securing A Stronger Position

    Currently enjoying a significant upswing on the American stock market, Clearmind Medicine Inc. (NASDAQ: CMND) is in a strong position. As of the most recent update during the current trading session, Clearmind’s stock has experienced a noteworthy 42.03% rise, culminating in a trading value of $2.94. This encouraging trend for CMND shares comes after Clearmind played a crucial role in an important conference.

    With great pride, Clearmind (CMND) announces today that its Type A meeting with the US Food and Drug Administration (FDA) has concluded successfully. The company’s clinical study of the patented CMND-100 chemical, based on MEAI, intended to treat Alcohol Use Disorder (AUD) through its novel psychedelic-based therapy, was the main topic of discussion during this conference.

    Clearmind confirms that they had an intelligent and fruitful conversation with the FDA recently. The business is now prepared to move forward with U.S. regulatory approval, providing millions of people who are struggling with AUD with a possible ray of hope. The innovative method used by Clearmind seeks to overcome the problems with the available therapy choices.

    Concurrently, Clearmind considers its successful partnership with SciSparc in 2023. CMND began the year by submitting six provisional patent applications to the USPTO, which described novel blends of upcoming psychedelic-derived substances. These applications represent a calculated step in Clearmind’s continuing collaboration with clinical-stage pharmaceutical firm SciSparc, which specializes in treating disorders of the central nervous system.

    The submitted patent applications are in line with Clearmind’s objective to provide safer and more efficient therapies, enhancing the therapeutic alternatives available to patients suffering from mental health illnesses by growing its portfolio of intellectual property (IP). The goal of this endeavor is to create transformational medications that minimize expenses while providing safety, effectiveness, and synergy.

    Any assets resulting from this partnership will be jointly held by Clearmind and SciSparc, in accordance with the collaboration agreement announced on March 8, 2022, demonstrating their continued dedication to delivering cutting-edge solutions in the industry.

  • Why Clearmind (CMND) Stock Remained Surging After-Hours?

    Why Clearmind (CMND) Stock Remained Surging After-Hours?

    Clearmind Medicine Inc. (NASDAQ: CMND) shares demonstrated sustained upward momentum following the market’s closure on Tuesday. The stock of Clearmind surged by 7.09%, reaching $4.68 in the extended trading session, following a notable 14.10% increase in the regular session, concluding at $4.37. The surge in CMND stock followed remarkable trial results.

    Clearmind (CMND) has officially disclosed positive outcomes in its endeavors to address addiction, particularly focusing on cocaine addiction. This pioneering achievement revolves around Clearmind’s inventive psychedelic molecule, MEAI, representing a significant breakthrough in the ongoing battle against addiction.

    The conducted trial, spearheaded by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center in Bar Ilan University, Israel, builds upon a prior experiment that showcased a substantial reduction in cocaine-induced cravings in rats treated with MEAI.

    These previously revealed results serve as a ray of optimism, illustrating MEAI’s potential efficacy in mitigating conditions linked to cocaine use. CMND’s distinctive psychedelic compound has exhibited noteworthy outcomes in pre-clinical trials targeting cocaine addiction, suggesting a potential paradigm shift in addressing the intricate challenges posed by this addiction, which currently lacks a dedicated treatment.

    Clearmind’s inventive strategy represents a transformative leap forward in tackling a global crisis. Considering the millions worldwide grappling with cocaine addiction, the successful utilization of MEAI could revolutionize treatment approaches and instill fresh optimism for those ensnared in the cycle of addiction.

    The groundbreaking research has led to a patent application in the United States as part of the ongoing collaboration with SciSparc, a specialized clinical-stage pharmaceutical company dedicated to central nervous system disorder therapies. The collaboration specifically focuses on integrating Clearmind’s MEAI, a unique proprietary psychedelic treatment for addiction, with SciSparc’s CannAmide.

    Within this collaborative effort, Clearmind has filed a provisional patent application related to cocaine addiction. As Clearmind Medicine persists in leading the way in the realm of psychedelic medicine, this development underscores the company’s unwavering commitment to unlocking the latent potential of psychedelic compounds in the realm of medical treatment.

  • Clearmind Medicine Inc. (CMND) Sees Pre-Market Surge With Breakthroughs in Treatment

    Clearmind Medicine Inc. (NASDAQ: CMND), a pre-clinical pharmaceutical company specializing in developing psychedelic medicines, is witnessing a significant surge in pre-market trading volume.

    With market participants anticipating a double-digit price increase, the company’s innovative treatments for various health problems are attracting attention and fueling expectations for its future growth.

    Bullish Indicators on CMND and Possible Short Squeeze

    Market participants are closely monitoring Clearmind Medicine Inc. (CMND) as they believe the company is significantly undervalued and subject to heavy short selling, with a short interest exceeding 22%.

    Despite the stock’s moderate Relative Strength Index (RSI) of 36.6, traders are observing an emerging golden crossover pattern, a bullish technical indicator. This trend has sparked excitement among investors, fueling expectations of a substantial price surge. With the anticipation of further upward momentum, bulls are eagerly following CMND’s rally, hoping for a favorable outcome.

    Clearmind Medicine’s Potential Breakthrough in AUD Treatment

    Clearmind Medicine Inc. has obtained Ethics Committee approval for its CM-CMND-001 Phase I/II clinical trial at Israel’s IMCA center, targeting alcohol use disorder (AUD).

    With the alcohol treatment market estimated to be a $35 billion annual industry in the U.S. alone, Clearmind’s $4 million market cap seems disproportionately small given the total addressable market opportunity. Current AUD therapies often have limited effectiveness, high relapse rates, and adverse effects.

    However, CMND-100, Clearmind’s MEAI-based compound, has shown promising results in pre-clinical studies, significantly reducing alcohol cravings and consumption with a favorable safety profile. The once-a-day oral capsule has the potential to revolutionize AUD treatment and enhance patient compliance.

    Conclusion

    Clearmind Medicine Inc. (CMND) has experienced a surge in pre-market volume, attracting attention and fueling expectations for its innovative treatments.

    Market participants anticipate bullish indicators and closely watch for a potential short squeeze. CMND’s breakthrough compound shows promise in revolutionizing alcohol use disorder treatment, generating further interest.